Zoetis | ZTS | Long at $156.94
Zoetis 
ZTS, the largest global animal health company, generated more than $9 billion in revenue in 2024 and earnings have grown 9.3% per year over the past 5 years. Free cash flow for FY2024 was over $2.2 billion. Dividend consistently raised every year for the past for years (currently 1.28%). The growth of the company isn't expected to slow any time soon, and I believe the animal health care market will grow right alongside the human health care market - if not potentially faster (people love their pets).
Thus, at $156.94,ZTS is in a personal buy zone. There may be some near-term risk with the potential for a daily price-gap close near $136.00, but I personally view that as an even better buy opportunity (unless fundamentals change).
Targets
ZTS, the largest global animal health company, generated more than $9 billion in revenue in 2024 and earnings have grown 9.3% per year over the past 5 years. Free cash flow for FY2024 was over $2.2 billion. Dividend consistently raised every year for the past for years (currently 1.28%). The growth of the company isn't expected to slow any time soon, and I believe the animal health care market will grow right alongside the human health care market - if not potentially faster (people love their pets). Thus, at $156.94,
ZTS is in a personal buy zone. There may be some near-term risk with the potential for a daily price-gap close near $136.00, but I personally view that as an even better buy opportunity (unless fundamentals change).Targets
- $170.00
- $180.00
- $200.00
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.